Hua Xiang

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Venues

Journal of medicinal chemistry

Chemical science

MedChemComm

China Pharmaceutical University

China Pharmaceutical University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

China Pharmaceutical University Dec 01 2003

China

Prof :: Medicinal Chemistry

Education History

China Pharmaceutical University Sep 01 2000 - Dec 01 2003

China

PHD :: Medicinal Chemistry

Publications

Maoxu Xiao, Si Ha, Jiacheng Zhu, Wenxiang Tao, Zixuan Fu, Hanlin Wei, Qiangqiang Hou, Guoshun Luo, Hua Xiang
Structure-Activity Relationship (SAR) Studies of Novel Monovalent AR/AR-V7 Dual Degraders with Potent Efficacy against Advanced Prostate Cancer. Journal of medicinal chemistry 67 (7) (2024)
Luyu Ma, Wei Chen, Ming Yang, Si Ha, Shuangshuang Xiong, Jiacheng Zhu, Hua Xiang, Guoshun Luo
Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors. Journal of medicinal chemistry 67 (5) (2024)
Luyu Ma, Wei Chen, Ming Yang, Si Ha, Shuangshuang Xiong, Jiacheng Zhu, Hua Xiang, Guoshun Luo
Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors. Journal of medicinal chemistry 67 (5) (2024)
Maoxu Xiao, Si Ha, Jiacheng Zhu, Wenxiang Tao, Zixuan Fu, Hanlin Wei, Qiangqiang Hou, Guoshun Luo, Hua Xiang
Structure-Activity Relationship (SAR) Studies of Novel Monovalent AR/AR-V7 Dual Degraders with Potent Efficacy against Advanced Prostate Cancer. Journal of medicinal chemistry 67 (7) (2024)
Maoxu Xiao, Si Ha, Jiacheng Zhu, Wenxiang Tao, Zixuan Fu, Hanlin Wei, Qiangqiang Hou, Guoshun Luo, Hua Xiang
Structure-Activity Relationship (SAR) Studies of Novel Monovalent AR/AR-V7 Dual Degraders with Potent Efficacy against Advanced Prostate Cancer. Journal of medicinal chemistry (2024)
Luyu Ma, Wei Chen, Ming Yang, Si Ha, Shuangshuang Xiong, Jiacheng Zhu, Hua Xiang, Guoshun Luo
Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors. Journal of medicinal chemistry (2024)
Si Ha, Guoshun Luo, Hua Xiang
A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives. Journal of medicinal chemistry (2022)
Guoshun Luo, Xin Lin, Antonio Vega-Medina, Maoxu Xiao, Guolong Li, Hanlin Wei, Carlos A Velázquez-Martínez, Hua Xiang
Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation. Journal of medicinal chemistry 64 (23) (2021)
Xinyu Li, Binyu Shi, Yu Teng, Yu Cheng, Huizhu Yang, Jiurong Li, Lianjian Wang, Siying He, Qidong You, Hua Xiang
Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors. MedChemComm 10 (2) (2019)
Fenghua Kang, Jiayi Zhu, Jianbing Wu, Tian Lv, Hua Xiang, Jide Tian, Yihua Zhang, Zhangjian Huang
O2-3-Aminopropyl diazeniumdiolates suppress the progression of highly metastatic triple-negative breast cancer by inhibition of microvesicle formation via nitric oxide-based epigenetic regulation. Chemical science 9 (34) (2018)

Hua Xiang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hua Xiang